Alnylam Pharmaceuticals Receives Upgrade from Freedom Capital Markets Amid Amvuttra Growth

Shares of Alnylam Pharmaceuticals (ALNY) rose by 6.83% on Tuesday, February 17, 2026, following an upgrade from Freedom Capital Markets. Despite a lowered price target, the firm cited strong performance of the drug Amvuttra as a key driver for the increased optimism.

Analyst Upgrade Details

Freedom Capital Markets, led by analyst Ilya Zubkov, upgraded Alnylam from a Hold rating to a Buy rating . The firm simultaneously lowered its price target for the stock from $470 to $410 per share , .

Amvuttra’s Performance

Zubkov highlighted the exceptionally robust sales of Amvuttra, a drug used to treat transthyretin amyloid cardiomyopathy (ATTR-CM), in both domestic and international markets . He anticipates this positive momentum will continue throughout the year. Though, he cautioned that potential pricing pressures could impact the company’s fundamentals in the next two to three years.

Recent Financial Results

The upgrade comes shortly after Alnylam reported its fourth-quarter and full-year 2025 results, which disappointed investors due to a miss in revenue estimates despite a bottom-line beat.

Additional Analyst Coverage

Canaccord Genuity’s Whitney Ijem similarly raised her price target on Alnylam to $429 per share from $415 on the same day .

Key Data Points (February 17, 2026)

• Today’s Change: 6.83%
• Current Price: $335.88
• Day’s Range: $315.63 – $336.21
• 52-Week Range: $205.87 – $495.55
• Volume: 1.5M
• Market Cap: $42B
• Gross Margin: 81.64%